HC Wainwright Has Bullish Estimate for TSE:BCT Q2 Earnings

BriaCell Therapeutics Corp. (TSE:BCT) – HC Wainwright increased their Q2 2025 EPS estimates for BriaCell Therapeutics in a research note issued on Monday, February 3rd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($2.83) for the quarter, up from their prior estimate of ($5.70). HC Wainwright also issued estimates for BriaCell Therapeutics’ Q3 2025 earnings at ($1.63) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($3.57) EPS, FY2026 earnings at ($2.14) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($1.01) EPS and FY2029 earnings at ($0.35) EPS.

BriaCell Therapeutics Stock Down 11.0 %

BriaCell Therapeutics stock opened at C$5.77 on Wednesday. BriaCell Therapeutics has a 52-week low of C$5.68 and a 52-week high of C$84.90. The firm’s fifty day moving average is C$1.66 and its 200 day moving average is C$1.24. The company has a market cap of C$206.80 million, a price-to-earnings ratio of -11.54 and a beta of 1.83.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.